News

Scientists have discovered that the individual contribution of gene variants known to increase the risk of Parkinson’s disease can be influenced by other genes and dictate disease age of onset. These findings, from the study “SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at…

A Phase 2 clinical trial of SEP-363856, an oral treatment candidate for people with Parkinson’s psychosis, is now recruiting patients across the U.S. SEP-363856 is a candidate therapy being developed by Sunovion to treat schizophrenia, and the hallucinations and delusions linked to Parkinson’s disease. It is designed to act as…

The Silverstein Foundation for Parkinson’s with GBA together with Q-State Biosciences have launched Chamishi Therapeutics, a company aiming to develop innovative treatments for Parkinson’s disease and other neurodegenerative diseases. Chamishi will initially focus on developing antisense oligonucleotide (ASO) therapies for Parkinson’s patients carrying mutations in the…

Researchers have found a compound that can rescue dopaminergic neurons from cell death and improve locomotor activity in fly models of Parkinson’s disease. Their findings were published in a study, “Miro1 Marks Parkinson’s Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson’s Models,” in the journal…

Although it may be protective against infections, a specific mutation in the LRRK2 gene — the gene linked to most inheritable mutations that can cause Parkinson’s disease — may increase Parkinson’s risk by promoting inflammation in the brain, according to new research. The study, “Lrrk2 alleles…

The National Institutes of Health has awarded a $2.9 million grant to a Feinstein Institutes for Medical Research scientist working to better understand and prevent dyskinesia, a common side effect of the levodopa used to manage motor symptoms of Parkinson’s disease. The five-year award went to David Eidelberg,…

Treatment with Nuplazid (pimavanserin), approved in the U.S. for treating hallucinations and delusions associated with Parkinson’s psychosis, eased depression and sleep problems in patients with Parkinson’s, according to results from a Phase 2 clinical trial. The research, “Open-Label Study of Pimavanserin Patients…

Using Cala Health’s non-invasive therapeutic device Cala Trio for 40 minutes twice daily effectively helped to reduce hand tremors within three months, results from a clinical study show. The results, “Study Design, Baseline Demographics, and Interim Results from the Prospective Study for Symptomatic Relief of Essential…

Oral treatment with tavapadon eased motor symptoms and was well-tolerated by patients with early-stage Parkinson’s, according to data from a Phase 2 clinical trial. Cerevel Therapeutics’ tavapadon (formerly known as PF-06649751) is a selective partial agonist of the dopamine D1 and D5 receptors, and is…

The Parkinson’s Foundation’s fourth annual Spanish-language conference, set for Oct. 19 in Norwalk, California, will provide the latest information about Parkinson’s disease treatment and management. Called “Hacia Adelante: Navegando el Mar del Parkinson’s” (“Forward: Sailing the Parkinson’s Sea”), the free conference is for patients, families, and…